SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies receives USFDA’s approval for Canagliflozin Tablets

06 Dec 2023 Evaluate

Indoco Remedies has received tentative approval from the US Food and Drug Administration (USFDA) for Abbreviated New Drug Application (ANDA) for Canagliflozin Tablets 100 mg and 300 mg, a generic equivalent of the Reference Listed Drug, Invokana Tablets 100 mg and 300 mg, of Janssen Pharmaceuticals, Inc. This product will be manufactured by Indoco Remedies, at their manufacturing facility located at Goa (Plant -I) in India. Canagliflozin improves glycemic control in adults with type 2 diabetes mellitus.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.


Indoco Remedies Share Price

226.85 -1.10 (-0.48%)
07-May-2026 11:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1827.75
Dr. Reddys Lab 1299.20
Cipla 1374.40
Zydus Lifesciences 939.35
Lupin 2471.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×